Major Players - Epinephrine Industry

Growing government and insurance agency backing for generic drugs will fuel the rise of the epinephrine industry. The exorbitant cost of the EpiPen created by Mylan NV is a major factor in the manufacturers' decision to launch more affordable generic epinephrine solutions. Support from regulatory bodies is anticipated to speed up the approval of generic versions of medications, enabling the introduction of drug alternatives without compromising clinical effect or safety profile. For instance, the FDA commissioner announced plans to quicken the creation of generic versions that mix a medication and a device in October 2017. IEpinephrine is offered in a variety of dosages and concentrations for administration through a variety of channels and for a variety of indications, including respiratory problems. Asthma is a major contributor to chronic respiratory diseases (CRDs), which affect more than 1 billion people globally and can persist throughout a person's lifetime, according to the World Health Organization (WHO). According to the WHO in 2017, there were over 300 million asthma sufferers in the world in 2013; by 2025, that number is predicted to rise to over 400 million.

According to Coherent Market Insights, The size of the global Epinephrine Market, which was estimated at US$ 2,040 million in 2017, is anticipated to grow at a CAGR of 11.0% from 2018 to 2026.

Market Players in the Epinephrine Industry:

1. Teva Pharmaceutical Industries Ltd.

The company is headquartered in Tel Aviv, Israel, and was established in 1901. Although it specialises on generic drugs, it also has certain ancillary commercial interests in pharmaceutical active ingredients and, to a lesser extent, patented drugs. Teva's ambitious climate objectives will have received external validation on January 19, 2023, according to the Science Based Goals programme (SBTi). Teva declared on January 9th, 2023, that the federal opioids deal will move through following widespread state backing.

2. Mylan NV,

The firm, founded in 1961, has its headquarters in Canonsburg, Pennsylvania, United States. The business manufactures active pharmaceutical ingredients, has a specialist division devoted to respiratory, allergy, and psychiatric therapies, and is a global generic and specialty medicines company. While the coronavirus 2019 (COVID-19) pandemic continues to evolve, Mylan stated in July 2020 that its Remdesivir would be commercially released in India under the brand name DESREMTM.

3. Pfizer Inc.,

The company was established in 1849, and it is based in Manhattan, New York City. The medical specialties of immunology, cancer, the heart, endocrinology, and neurology are all benefited by Pfizer's research and production of drugs and vaccines. In October 2022, the company successfully purchased the calcitonin gene-related peptide programmes of Biohaven Pharma. In April 2021, Amplyx Pharmaceuticals and the antifungal medication fosmanogepix were acquired by Pfizer. (APX001).

4. Impax Laboratories, Inc.

The company was started in 1999 and is based in Hayward, California, United States. Using its drug delivery technology, Impax Laboratories, LLC creates, produces, and sells both single-source and multi-source pharmaceutical products. The company specializes in the creation of branded products as well as controlled release generics and specialty items.

5. Kaleo, Inc.

The firm was founded in 2005 and is based in Richmond, Virginia. The company delivers medical items and a pipeline devoted to offering solutions for life. A company called Kaléo is dedicated to providing patients and their families with meaningful and innovative healthcare products and solutions.

6. Adamis Pharmaceuticals Corporation

The company was started in 2006 and is based in California, United States. A speciality biopharmaceutical firm, Adamis Pharmaceuticals is largely focused on creating and marketing medications for a range of therapeutic conditions, such as allergy, opioid overdose, respiratory, and inflammatory disease.

7. Bausch Health Companies,

The company was started in 1959 and is based in Laval, Quebec, Canada. It creates, produces, and sells pharmaceutical goods and name-brand generic medications, primarily for eye health, neurology, gastrointestinal disorders, and skin conditions. In collaboration with TerraCycle, Bausch & Lomb launched the Biotrue® Eye Care Recycling Program in October 2021 in the United States.

*Definition:

The adrenal glands create epinephrine, often known as adrenaline, which is a hormone and neurotransmitter. The first line of treatment for anaphylaxis is epinephrine, which aids in reversing its symptoms.